ArticleThe Lancet. Oncology2024
Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study.
Article in The Lancet. Oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Understanding Equity in Cancer Prehabilitation Services in Wales: A Medical Record Review.Cancer reports (Hoboken, N.J.) · 2026Article
- Frequency and Natural History of Emergency General Surgery Conditions in Cancer Patients: A SEER-medicare Population Analysis.Annals of surgery · 2026Article
- Inequalities in Gastrointestinal Care Provision in the United Kingdom.Digestive diseases and sciences · 2026Review
- Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity.Nature reviews. Cancer · 2025Review
- Article
- Characteristics of interventions aimed at reducing inequalities along the cancer continuum: A scoping review.International journal of cancer · 2025Article
- Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England.British journal of cancer · 2025Article
- Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.BJU international · 2025Article
- Design, Synthesis, and Biological Evaluation of Novel Hydroxyamidine Derivatives as Indoleamine 2,3-Dioxygenase 1 Inhibitors.ACS medicinal chemistry letters · 2025Article
- The estimated incidence of uterine corpus cancers among permanent residents in mainland China using Bayesian spatial modeling.Scientific reports · 2025Article
- A precision image-guided model of stereotactic ablative radiotherapy for hepatocellular carcinoma.Disease models & mechanisms · 2025Article
- Seeing red..? Co-design of a culturally tailored uterine cancer awareness intervention for Asian and Black ethnic minority groups.Gynecologic oncology reports · 2025Article
- Health inequalities in hepatocellular carcinoma surveillance, diagnosis, treatment, and survival in the United Kingdom: a scoping review.BJC reports · 2025Article
- You Need to Know: evaluation of a uterine cancer awareness campaign for Black and Asian ethnic minority women in North East London.BMJ public health · 2025Article
- Pesticides and risk of pancreatic adenocarcinoma in France: a nationwide spatiotemporal ecological study between 2011 and 2021.European journal of epidemiology · 2024Article
- Health inequalities in cancer care: a literature review of pathways to diagnosis in the United Kingdom.EClinicalMedicine · 2024Review
- Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment.Frontiers in immunology · 2024Review
- The Impact of the COVID-19 Pandemic on Incidence and Short-Term Survival for Common Solid Tumours in the United Kingdom: A Cohort Analysis.Clinical epidemiology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundCancers are the leading cause of death in England. We aimed to estimate trends in mortality from leading cancers from 2002 to 2019 for the 314 districts in England.
methodsWe did a high-resolution spatiotemporal analysis of vital registration data from the UK Office for National Statistics using data on all deaths from the ten leading cancers in England from 2002 to 2019. We used a Bayesian hierarchical model to obtain robust estimates of age-specific and cause-specific death rates. We used life table methods to calculate the primary outcome, the unconditional probability of dying between birth and age 80 years by sex, cancer cause of death, local district, and year. We reported Spearman rank correlations between the probability of dying from a cancer and district-level poverty in 2019.
findingsIn 2019, the probability of dying from a cancer before age 80 years ranged from 0·10 (95% credible interval [CrI] 0·10-0·11) to 0·17 (0·16-0·18) for women and from 0·12 (0·12-0·13) to 0·22 (0·21-0·23) for men. Variation in the probability of dying was largest for lung cancer among women, being 3·7 times (95% CrI 3·2-4·4) higher in the district with the highest probability than in the district with the lowest probability; and for stomach cancer for men, being 3·2 times (2·6-4·1) higher in the district with the highest probability than in the one with the lowest probability. The variation in the probability of dying was smallest across districts for lymphoma and multiple myeloma (95% CrI 1·2 times [1·1-1·4] higher in the district with the highest probability than the lowest probability for women and 1·2 times [1·0-1·4] for men), and leukaemia (1·1 times [1·0-1·4] for women and 1·2 times [1·0-1·5] for men). The Spearman rank correlation between probability of dying from a cancer and district poverty was 0·74 (95% CrI 0·72-0·76) for women and 0·79 (0·78-0·81) for men. From 2002 to 2019, the overall probability of dying from a cancer declined in all districts: the reductions ranged from 6·6% (95% CrI 0·3-13·1) to 30·1% (25·6-34·5) for women and from 12·8% (7·1-18·8) to 36·7% (32·2-41·2) for men. However, there were increases in mortality for liver cancer among men, lung cancer and corpus uteri cancer among women, and pancreatic cancer in both sexes in some or all districts with posterior probability greater than 0·80.
interpretationCancers with modifiable risk factors and potential for screening for precancerous lesions had heterogeneous trends and the greatest geographical inequality. To reduce these inequalities, factors affecting both incidence and survival need to be addressed at the local level.
fundingWellcome Trust, Imperial College London, UK Medical Research Council, and the National Institute of Health Research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.